Overview

SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies

Status:
Not yet recruiting

Trial end date:
2022-10-15

Target enrollment:

Participant gender:

Summary

This is an open-label, dose escalation, Phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy in patients with relapsed or refractory multiple myeloma and other hematological malignancies

Phase:

Phase 1

Details

Lead Sponsor:

Hangzhou Sumgen Biotech Co., Ltd.

Treatments:

Antibodies, Monoclonal